hLF(1-11) seems to be an outstanding AMP candidate for the treatment of infections in humans through its resistance against proteolytic degradation, its human origin, the possibilities for combination therapy, the cytotoxic activity through the accumulation of CA2+ inside the target cells, no side effects in humans up to 5 mg per dose, and the stimulating effect on monocyte differentiation into macrophages. The gene discussed is HLF; the disease is infection.